Skip to: Project management, Secondary data analysis, Intelligence programmes, Market research.

High quality secondary data analysis

This is the cornerstone of what Carogail can offer pharmaceutical companies. There is such a vast range of secondary data now available, much is purchased and often not used to its fullest extent due to time constraints. Carogail can analyse large quantities of material and summarise them down to a set of key conclusions and actionable recommendations relevant to any particular objective. This can be done as larger one-off projects (eg. situational analysis for a specific disease area), or as smaller regular tracking exercises (eg. monitoring newswires for particular topics).

Experience includes extensive use of:

  • Newswires
  • Broker reports
  • Regulatory data
  • Epidemiological data
  • Pipeline data
  • Sales data
  • Conference reports
  • Syndicated reports published by large secondary data providers such as IMS, Decision Resources and Datamonitor.

Recent projects have included:

  • A packaging review for Japan, Italy and the UK, leading to changes in secondary packaging design for pharmaceuticals that help both to reassure patients and offer customers greater control over how medication impacts their lives.
  • A regional review of the Chinese market (focused in the primary care setting), allowing global teams to understand how global brand strategies will need to be adapted in China to maximise success.

Continue to: Development of competitor intelligence programmes.